Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia

• Hassan Awada,
• Mina Abdelmalek,
• Tara Cronin,
• Jeffrey Baron,
• Zakariya Kashour,
• Farhan Azad,
• Muhammad Salman Faisal,
• Mark Faber,
• Matthew Gravina,
• Pamela J. Sung,
• Steven D. Green,
• Amanda Przespolewski,
• James E. Thompson,
• Elizabeth A. Griffiths,
• Eunice S. Wang

Affiliations

Hassan Awada

Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center

Mina Abdelmalek

Department of Medicine, State University of New York at Buffalo

Tara Cronin

Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center

Jeffrey Baron

Department of Pharmacy, Roswell Park Comprehensive Cancer Center

Zakariya Kashour

Department of Medicine, State University of New York at Buffalo

Farhan Azad

Department of Medicine, State University of New York at Buffalo

Muhammad Salman Faisal

Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center

Mark Faber

Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center

Matthew Gravina

Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center

Pamela J. Sung

Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center

Steven D. Green

Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center

Amanda Przespolewski

Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center

James E. Thompson

Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center

Elizabeth A. Griffiths

Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center

Eunice S. Wang

Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center